Background: Adipose and adipose derived regenerative cells (ADRCs) play an increasing role in androgenetic alopecia (AGA).
A c c e p t e d M a n u s c r i p t Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women and is characterized by progressive hair loss of the scalp due to a combination of genetics and androgens.
AGA is reported to affect up to 70% of caucasian men and 42% of women during the course of a lifetime. 1 The pathogenesis of this progressive condition is based on miniaturization of the hair follicles and gradual conversion of terminal hairs into vellus hairs while the anagen phase shortens. 2 The degree of hair loss in the male patient is classified by the Norwood Hamilton Classification (Figure 1 ) in which hair loss is staged from Class 1 (absence of thinning) to Class 7 (very advanced hair loss), while for female hair loss the Savin scale is used for staging hair loss ( Figure 2 ). Initial treatment for AGA is usually medical and the two FDA approved medications are minoxidil and finasteride. Apart from these, in the past several years there has been an increased interest in low-level laser therapy (LLLT/photobiomodulation) and prostaglandins as well as in regenerative therapies such as microneedling, platelet rich plasma (PRP) and stem cell treatments.
Hair transplantation remains a surgical option to restore hair in which hair is harvested from a "permanent" donor zone of the scalp (occipital and parietal areas), and then placed into areas affected with hair loss.
The potential of regenerative medicine, especially the use of adipose tissue and Adipose Derived Regenerative Cells (ADRCs) is growing in all fields of medicine. Scientific focus on the role of this tissue in the hair growth cycle has shown correlation between these two forms of cell therapy and hair growth. 3 It has been established that the adipose tissue is an integral part of the normal hair cycle and it is reported that the hair loss and decreased volume of subcutaneous tissue in the scalp occur together. 3 ADRCs maintain the ability to differentiate into mesenchymal lineage cells but also secrete various growth factors that seem to play a role in neovascularization, which is important in treating various hair loss conditions. 4 Addition of adipose tissue in the scalp thickens the subcutaneous layer that is typically associated with thinning in androgenetic alopecia. 5 Cell enrichment of adipose tissue with ADRCs has been shown to prolong graft retention as described in many preclinical and clinical studies to date. 6 Zhu et al have used an animal model to show that coating one volume of adipose tissue with cells isolated from another volume of adipose tissue resulted in an approximate doubling of graft retention at six and nine months. 6 Most of the studies published on hair regeneration using ADRCs are in either cultured hair follicles, animal models, or in human subjects using adipose-derived stem cell-conditioned medium (ADSC-CM). [7] [8] [9] Apart from ADSC-CM application, there was one study where stromal vascular fraction (SVF), with autologous adipose tissue, was utilized on 9 patients with a follow-up of six months. 10 Despite some limitations of the study (small sample size, poor follow-up data, non-blinded analysis), this study showed that SVF with fat injection is a safe and promising alternative approach to treating hair loss in men and women and served as the precursor to the phase II investigation described in this report. Following informed consent and screening evaluations, eligible subjects underwent preoperative testing. Subjects randomized into the study were assigned the treatment corresponding to the next available number in a computer-generated randomization schedule. The randomization process was managed by an independent contract research organization (Peachtree BioResearch Solutions, Marietta GA) and occurred on the procedure day, prior to the start of liposuction. Subjects underwent a fat harvest using local anesthesia with or without conscious sedation. Subjects were randomly assigned to receive a fat graft cell enriched with ADRCs (available in 2 different doses), a fat graft without cell enrichment (fat alone control), or a saline injection (no-fat control) in a 2:2:2:1 ratio.
The study included both male and female adult subjects with a diagnosis of AGA and a body mass index <40kg/m 2 . Males had hair loss consistent with Grades III, IIIA, III-Vertex, IV, IV-A, based on Norwood-Hamilton Classification. Females had hair loss consistent with Grades I-3, I-4, II-1, II-2 based on the Savin scale. Subjects must have maintained a consistent hair length and natural hair color, without the use of any coloring agents, during the study period. Subjects who used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening were not eligible. Subjects who previously failed, or were deemed nonresponsive to, a previous experimental hair loss treatment were not eligible. Subject with previous hair transplantation, cell treatment, micro needling, or any other treatment in the last 6 months in the scalp were not eligible. The key primary inclusion criteria included both males and females with a diagnosis of early patterned hair loss as defined by accepted visual scales. Patients were excluded with a recent (within 6 months) hair transplant and/or use of topical hair growth medications. In addition, those subjects having used oral medications to promote hair growth within the last 12 A c c e p t e d M a n u s c r i p t months were also excluded. A complete listing of inclusion/exclusion criteria can be found at www.clinicaltrials.gov (NCT02503852) and are listed below:
The inclusion criteria included males with a diagnosis of Alopecia Androgenetica; females with a diagnosis of Alopecia Androgenetica; males with hair loss consistent with Grades III, IIIA, III-Vertex, IV, IV-A, based on Norwood-Hamilton Scale (Figure 1 ); females with hair loss consistent with Grades I-3, I-4, II-1, II-2 based on the Savin Scale ( Figure 2 ); patients who provided written informed consent and complied with the study requirements; women of childbearing potential with a negative pregnancy test at screening visit who agreed to maintain two forms of contraception for the duration of the study; subjects who were willing to maintain a consistent hair length and natural hair color, without the use of any coloring agents, during the study period; subjects with the ability to complete study procedures, patient surveys, and agreed to photographs; subjects who were ≥ 18 years of age and who had a body mass index (BMI) of < 40kg/m 2 .
The exclusion criteria included subjects who have used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening; treatment with an investigational product or procedure within 30 days or plans to participate in another clinical study; subjects who had previously failed or has been deemed non-responsive to a previous experimental hair loss treatment; subjects must have had no previous hair transplants, cell treatment, micro needling, or any other treatment in the last 6 months in the scalp; subjects who are currently suffering from an active autoimmune disease such as serum lupus erythematosus, or alopecia areata. Subject is currently suffering from dermatologic condition in the treatment area or has a significant scar in the hair treatment area that, in the opinion of the investigator, will make hair growth difficult (such as systemic burns, etc.); history of autoimmune disease or organ transplantation or a patient on immunosuppressive medication(s); diagnosis of cancer, receiving active treatment; active systemic infection; requires chronic antibiotics, systemic corticosteroids; use of systemic agents that increase bleeding or clotting, or disorders associated with these effects, including patients receiving GIIB/IIIa inhibitors within 2 weeks prior to the study procedure through to 1 week after the study procedure; clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator; prior surgery in the treatment area; any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise dermatologic, hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk; pregnant or lactating women or women trying to become pregnant; known allergic reaction to components of study treatment and/or study injection procedure; subject has any disorder that may prevent compliance to study procedures and visits; subject who is part of the study staff, a family member or friend; diabetes or thyroid disorder; subject who has a sensitive, irritated, or abraded scalp area;
women who have an alternate diagnosis that is associated with hair loss; BMI < 18kg/m 2 ; clinically 
Injection
After liposuction was completed, subjects had, under a ring block local anesthesia, a subcutaneous (hypodermis) scalp injection of either 0.1 ml/cm 2 of Puregraft purified autologous fat or saline (no-fat control) using a blunt-tip cannula. Using standard fat grafting technique, cannula were advanced at strategically placed insertion points and tunneled to the area of treatment. This was followed by separate second intradermal injections (multiple, covering the area of treatment) of either 0.1 ml/cm 2 of ADRCs (available in 2 different doses), a visually-matched blood saline solution (fat alone control), or saline (no-fat control) using a 1-inch length standard 25G needle directly through the scalp. These injections were performed at a 45-degree angle to the scalp and injection of cells was performed upon withdrawal of the needle. A schematic of the procedure is shown in Figure 3 .
All subjects underwent clinical evaluations and laboratory testing prior to and after the procedure. For each subject, the study duration included a screening period of up to 28 days and a 52week follow-up period.
Safety endpoints included the frequency of Adverse Events (AEs), Serious Adverse Events (SAEs), Unexpected Adverse Device Events (UADEs), changes in clinical laboratory test results (chemistry, hematology, and urinalysis), vital signs, and physical examination findings. In addition, an independent Data Monitoring Safety Board (DMSB) was commissioned to review safety data at various timepoints for the first forty (40) patients.
To assess efficacy, global and macrophotography were captured at baseline, 6 weeks, 24 weeks, and 52 weeks using the Global Hair Device and Macro Canon VEOS-SLR (Canfield Scientific, Inc., Fairfield, NJ) . This platform system uses a chin cup and head support attached to a camera (with accompanying flash) to provide consistent, fixed distance global photography. For macrophotography, a fixed size glass contact plate (defines the measurement site) is attached to the camera and is applied directly to the patient's skin to obtain the macrophotograph. To ensure the same location is measured each time, all patients first underwent a semi-permanent micro tattooing process prior to any data acquisition. Images captured at sites were securely uploaded, underwent a 3 rd -party (Canfield) quality assurance review, and evaluated using validated software in a blinded fashion by the vendor. Macrophotography included hair counts and hair widths for vellus (<30 microns in A c c e p t e d M a n u s c r i p t diameter), non-vellus (>30 microns in diameter), and total (vellus + non-vellus). In addition, investigator and subject satisfaction surveys were performed at 24 and 52 weeks. The analysis sets used were the intent-to-treat (ITT) population (all subjects randomized prior to liposuction), the pertreatment-evaluable (PTE) population (all randomized subjects who received treatment and for whom follow-up information was available), the modified ITT (mITT) population (all ITT subjects excluding six (6) subjects based on the reassessment of baseline hair loss category by the principal investigator), and the safety population (all treated subjects).
As a phase II, exploratory study, the primary endpoint was safety and tolerability of the procedure and as such, the investigators believed that a study design of 20 subjects per arm and a 10 patient no-fat saline control was adequate. Therefore, the sample size for the trial was set at 70 based on clinical considerations and was not based on formal power calculations. The authors believe this is consistent with exploratory phase II studies.
Safety and efficacy endpoints were summarized by treatment group using descriptive statistics (n, mean, standard deviation, median, minimum, and maximum) for quantitative variables and frequencies and percentages for categorical variables. Laboratory data were also summarized using shift tables between before procedure and at Day 1, post-procedure, with values categorized as less than lower limit of normal range, within normal range, and above upper limit of normal range.
All statistical tests were 2-sided, and statistical significance was assessed with respect to a nominal pvalue of 0.05. Related AEs were analyzed separately for those related to ADRCs and the delivery of ADRCs (ie, injection site telogen effluvium). Consistent with a phase II investigation, efficacy analyses were conducted on the ITT population, the PTE population and the mITT population (including ad hoc populations such as males with Norwood Hamilton III, females). Global photographic data were not included this quantitative analysis. The change from baseline at Week 24 and 52 in hair counts and hair width was analyzed using analysis of covariance (ANCOVA) models with adjustment for the baseline value.
RESULTS
A total of 71 subjects were randomized and treated in this study. This included 17 females and 54 males. The mean age of participants was 40.7 years (range, 24-73 years). Of the 71 subjects treated, a total of 60 (84.5%) completed the 12-month study. Loss to follow-up was the primary reason for discontinuation and mean time of follow-up was 46 weeks (range, 28 days-52 weeks). [AQ: Is this follow-up range correct?] None of the subjects were withdrawn due to adverse events.
Hair Count
Non-vellus hair, also known as terminal hairs, are the mature form of hair and are defined in this study as having a diameter greater than 30 microns. There were increases in non-vellus hair count for the low-dose ADRC group in the Baseline NW3 ad hoc subgroup at Week 6 (mean change from in non-vellus hair count between the low-dose ADRC group and the no-fat saline control was statistically significant (p=0.0318) at Week 24. This is represented in Figure 4 . Figure 5 demonstrates the percent change from baseline at 52 weeks for the Norwood-Hamilton III population. For this group of men with early hair loss, the effect observed at 24 weeks noted above was not maintained at 1-year (2% increase). For the corresponding control group, they maintained a loss of -4% at 52 weeks. This difference between the fat + low dose regenerative cell group and control group was not statistically significant. This result suggests that this therapeutic approach may drive short-term hair cycle activity but may need to be repeated or used in combination with other therapeutic approaches for sustained effect.
In the same NW3 ad hoc subgroup, statistically significant increases in total hair count (nonvellus + vellus) were observed for the low-dose ADRC group at Week 6 (p=0.0219) and Week 12 (p=0. 0434). This was also observed for the high-dose ADRC group at Week 6 (p=0.0465).
In the ITT group, there was a statistically significant change from baseline in hair count for the low-dose ADRC group at Week 6 (mean change from baseline, 13.65±18.01; 95% CI 5.22, 22.08). In this population, there were no apparent changes from baseline in hair count for any of the other treatment groups at Week 6, or for any of the treatment groups at Week 12, Week 24, or Week 52. There were no statistically significant changes in total hair count between the low-dose ADRC, high-dose ADRC, or fat alone control groups and the no-fat saline control group at any timepoint for the ITT population.
Hair Width
There were no statistically significant changes in total hair width between the low-dose ADRC, highdose ADRC, or fat alone control groups and the no-fat saline control group at any timepoint for the ITT population or for any of the sensitivity analyses. In the ITT population, other than an increase in hair width at Week 12 for the no-fat saline control group, the fat alone control group and the no-fat saline groups had decreased mean terminal hair widths at all timepoints. Evaluations of the ad hoc populations (mITT, Baseline NW3, male not Baseline NW3, and female) revealed a similar pattern of response to the ITT population for hair width.
In the Norwood-Hamilton III population, early increases in mean terminal hair width were observed at week 6, week 12, and week 24 for the low-dose group. These changes were not sustained at week 52. Figure 6 below illustrates the percent change from baseline in terminal hair width for the Norwood-Hamilton III population over the duration of the study. Week 12 for all of the questions. While the proportion of subjects with positive responses decreased at Week 24 compared to Week 12, that response level was sustained through Week 52 and was higher than the Week 6 response level for all but Question 4 (effectiveness of the procedure has been in slowing down the subject's hair loss).
 The fat alone control group had the highest proportion of subjects with positive responses at
Week 24 for all of the questions but was lower at Week 52 for all of the questions. Week 24 for Questions 1, 2, 3, and 4, but was lower at Week 52 for Questions 1, 2, and 3.
Safety Analyses
As the primary endpoint of the study was safety and tolerability, it was found that injections of fat grafts enriched with ADRCs were safe and well tolerated in subjects with AGA. There were no serious adverse events, deaths, or unexpected adverse device events in this study. There was no evidence of any clinically relevant changes in hematology or chemistry parameters and while some subjects had occasional hematology or clinical chemistry results that were abnormal, none were judged by the investigators to be clinically significant, and none were reported as AEs. There were no apparent changes in vital signs over the course of the study and no AEs were associated with vital sign abnormalities.
DISCUSSION
Androgenetic Alopecia (AGA) is the most common form of both male and female pattern hair loss.
For both sexes, the negative physical and psychological effects of AGA are well documented. In Stough's report, the authors indicate that while the condition may not appear to cause direct physical harm in men, hair can protect against sunburn, cold temperatures, mechanical injury, and ultraviolet light. 11 Beyond the physical, hair loss is known to psychologically affect the balding individual's selfperception. This is particularly true when looking at Female Pattern Hair Loss (FPHL), where Cash and co-workers reported that while AGA was a stressful experience for both sexes, it was substantially more distressing for women. 12 In sum, the impact of the condition is substantially functional as well as aesthetic in nature. Therefore, serious and thoughtful investigation to develop satisfactory treatment regimens is proper and necessary.
The current treatment regimen for AGA recommended by medical professionals is a spectrum ranging from noninvasive pharmacologic approaches to surgical transplantation of thousands of follicular units. Initial treatment of early alopecia is typically non-invasive and the 2 medications A c c e p t e d M a n u s c r i p t approved by the US Food and Drug Administration (FDA) today are minoxidil and finasteride. 13, 14 For minoxidil, it is reported that approximately one-third of subjects with AGA respond with new hair growth. 15 Both of these medicines carry untoward side-effects. In contrast, invasive transplantation options are generally not offered to subjects with early AGA and if so, require significant financial resources. As a result, there remains a significantly large gap between these medical and surgical options. Hence there is a distinct medical need for treatments specific to patients with early alopecia.
During hair follicle growth phase (anagen), the hair follicle extends deep into the rich dermal macroenvironment as it grows to maturity where it is surrounded by large lipid-filled adipocytes.
These intradermal adipocytes regenerate with faster kinetics than other adipose tissue depots and such growth parallels with the hair cycle, suggesting that an interplay exists between hair follicle cells and adipocyctes. 3 Thus, it has been established that adipose is an integral part of the normal hair cycle and it is hypothesized that telogen may be due to an absence of adipose tissue as it is reported that hair loss and a decrease in perifollicular adipocytes occur together. 3, 16 Therefore, the transplantation of adipose tissue, or autologous fat transfer (AFT), into the subcutaneous layer of fat in the scalp and into the dermis for purposes of stimulating hair growth is consistent with the reported literature that indicates hair loss and adipose loss occur in tandem.
In an AFT procedure, a subject's subcutaneous adipose tissue is readily aspirated from one location (most commonly the abdomen or thighs) and transferred into another depot of subcutaneous fat located throughout the body (eg, mid-face). These surgical techniques are well established throughout the aesthetic surgical literature. Currently, there are few, if any, minimally invasive, autologous cell therapeutic modalities being developed that address early alopecia. A previous pilot study using similar, but not identical methods described in this study, demonstrated stem cell enriched fat grafting represents a promising alternative approach for treating baldness in men and women. 10 The current study (the STYLE Trial) was a prospective, randomized, multicenter, device trial intended to evaluate the safety and efficacy of the Kerastem Therapy in the processing and preparation of an autologous fat graft enriched with ADRCs in the treatment of early AGA.
The authors' key take-aways from the exploratory STYLE study include 1) dosing matters, and the lower dose of ADRC enriched purified fat consistently performed better in both quantitative as well as qualitative methods; 2) this minimally-invasive approach was superior only in men with early hair loss and likely requires either additional treatments and/or combination with complementary therapies, and 3) this procedure was safe and well tolerated by patients.
Dosing Matters
In evaluating the dose response of subjects in STYLE, one of the dosing regimens was clearly superior. Namely, injection of purified fat with 0.5 x 10 6 ADRCs per cm 2 of scalp demonstrated a clear and consistent superior result. The importance of dosing is often under-appreciated in regenerative aesthetics. Furthermore, the data supported that more cells per area of scalp treated did A c c e p t e d M a n u s c r i p t not provide a better outcome. This seemingly paradoxical response has been reported previously in other stem cell therapy studies, notably those in cardiac therapies. 17 When applied to AGA, the authors hypothesize this may be related to the degree of local inflammation, which has been previously reported to play a role in patterned baldness. 18, 19 In looking at the make-up of the ADRCs, there is a relatively high percentage of tissue macrophages (approximately 25%). A relatively high dose of ADRCs injected into a local area of the scalp may promote micro inflammation and may be responsible for the inferior response. Additional studies are likely needed to further investigate this hypothesis, including the role of potential complementary therapies such as PRP, microneedling, and cultured stem cell therapies.
Early Hair Loss
One of the goals of a phase II exploratory study, besides proving safety and tolerability, is to determine feasibility and determine directionality. In analysis of the population and subpopulations of this investigation, the optimum results were seen in men with early hair loss (Norwood-Hamilton 3).
This does not appear to be a function of age, as the average age of men in this subpopulation was 41 years, which was also the average age of all participants. That said, it is understood in regenerative medicine approaches that the quality of autologous cells, 20 and perhaps the extent of existing disease, plays a role in the regenerative capacity of therapies. Applied to STYLE, perhaps men in the early stages of the complex process of patterned hair loss are best suited to respond to regenerative approaches (perhaps in combination with other therapies) and future studies will no doubt target this population given the strong signal. This is of particular relevance given the clear benefits of treatments addressing for this population.
Sustained Response, PRP, and the Role of Repeat Therapies
In the men with early hair loss who were observed to respond best to fat + low dose regenerative cells at 24 weeks, this effect appeared to diminish over time as seen at 52-weeks. While the relative trend between groups (eg, low dose vs. others) generally held, the authors assert that this cellular therapy would likely require repeat approaches and/or combination with other adjunct therapies including PRP, low-level laser therapy, microneedling, etc. Of note, poly therapy is historically a common approach to the treatment of patterned alopecia, likely reflecting the complex multi-factorial etiology underlying hair loss.
It is also worth noting for the reader that PRP is increasingly being explored as an intervention for treating early hair loss. This current study did not involve the study of PRP and therefore the authors are not in a position to directly compare and contrast the efficacy of the two techniques. A direct comparison employing published reports is also limited by considerably varying methods of measuring and reporting hair growth. However, in a recent meta-analysis on the use of PRP, Gupta and co-workers reported a Standardized Mean Difference (SMD) in hair density of 0.58, A c c e p t e d M a n u s c r i p t in favor of PRP. 21 While this reported benefit is encouraging, the authors also recommend initial repeated monthly sessions of PRP (once monthly ×3 treatments) followed by a 3-to 6-month maintenance period. Further, according to the International Society for Hair Restoration Surgery (ISHRS), no definitive regimen nor conclusive studies on the role of PRP efficacy exist. 22 While both cell-and platelet-based therapies show evidence supporting hair growth, both approaches are likely to benefit from repeated treatments and therefore must be made available as cost-effective solutions to patients. Furthermore, the investigators hypothesize that while cell-based approaches may initiate a stimulation of the hair cycle, frequent interventions are necessary to counter the constant forces of follicular miniaturization at work with genetic alopecia.
Study Limitations
The authors acknowledge the potential limitations of this study include a relatively small sample size for the findings in men with early hair loss (Norwood-Hamilton III). However, the robustness of the data, even with this small sample, speaks to the potential merit of the approach. In addition, the authors note the emerging role of alternative approaches (eg, PRP, microneedling) to the treatment of early hair loss and our work does not directly compare and contrast alternative approaches. Future work will address these limitations.
CONCLUSION
The straightforward technical aspects of this approach to hair loss are likely behind the positive safety data. In addition, subjects screened and enrolled into the study were generally healthy, with minimal co-morbidities. In short, this is an enriched fat grafting procedure in which practitioners comfortable with these standard techniques may be suited to explore this approach. In conclusion, the authors believe this novel regenerative approach is promising and warrants continued development in the treatment of early patterned hair loss.
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This article contains supplementary material located online at www.aestheticsurgeryjournal.com. hair counts. When compared to the control group within the same group at 24 weeks, this difference was found to be statistically significant. Of note, the group treated with fat and a high dose did not respond. The authors hypothesize this may be due to the presence of excess white blood cells involved with inflammation. Figure 5 . This figure demonstrates the percent change from baseline at 52 weeks for the Norwood-Hamilton III population. For this group of men with early hair loss, the effect observed at 24 weeks noted above was not maintained at 1 year (2% increase). For the corresponding control group, they maintained a loss of -4% at 52 weeks. This difference between the fat and a low dose regenerative cell group and the control group was not statistically significant. 
